RudaCure, une entreprise spécialisée dans le développement de traitements pour les troubles sensoriels, a annoncé le 3rd that its chronic traitement de la douleur (RCI002) a été sélectionnée comme supported project by the Korea Drug Development Fund (KDDF), and that optimization research to derive a composé principal will now begin in earnest.
RudaCure's RCI002 is a compound that selectively inhibits the activity of TRPV1, a key target known for developing powerful analgésique non narcotiques. Selon de l'entreprise preliminary research, the compound demonstrated TRPV1 inhibitory activity and reduced pain in douleur chronique animal models. Unlike existing TRPV1 antagonists, it does not cause abnormal fever, offering excellent efficacité analgésique with no significatif effets secondaires, giving it high potential for development as a safe treatment.
En particulier, l'entreprise expects synergistic effects for the optimization research of RCI002 through joint execution of this projet de soutien with the team of Professeur Park Cheol-gyu at Gachon University College of Medicine — a specialist in traitement de la douleur development who is participating as the lead institution.
Source: BioTimes (http://www.biotimes.co.kr)